The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

2017. Zepbound, an Eli Lilly drug, can now be prescribed to adults with “moderate-to-severe obstructive sleep apnea and obesity” to improve their sleep, a press release from the company said.

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved ... is a major step forward for patients with obstructive sleep apnea,” Dr. Sally Seymour ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The ...